Sign up for our newsletter


Remo Di Gregorio returns failed drug test for EPO at Paris-Nice

Joe Robinson
11 Apr 2018

Di Gregorio has been notified of offence for sample collected at Paris-Nice in March

Delko Marsielle Provence KTM rider Remy Di Gregorio has returned an Adverse Analytical Finding (AAF) for darbepoetin - commonly known as dEPO - at this year's Paris-Nice. The Frenchman has been notified and has the possibility of requesting the analysis of a B sample.

In a statement released by the UCI is stated that it 'announces that French rider Remy Di Gregorio was notified of an Adverse Analytical Finding (AAF) of darbepoetin (dEPO) in a sample collected on 8th March 2018 during Paris-Nice.'

It then reaffirmed that Di Gregorio has the chance to request the testing of a B sample and that following that 'in accordance with UCI Anti-Doping Rules, the rider has been provisionally suspended until the adjudication of the affair'.

Di Gregorio's team then released a statement confirming that the rider would have his contract terminated with immediate effect as a precautionary measure with team manager Frederic Rostaing writing that he felt 'ashamed and betrayed' by the result findings.

Di Gregorio returned this AAF at Paris-Nice, a race in which he finished 22nd on General Classification. The Frenchman also finished third on Stage 3 to Chatel-Guyon behind Jonathan Hivert and Luis Leon Sanchez.

Darbepoetin is is classified as 'Peptide Hormones, Growth Factors, Related Substances and Mimetics' and is also a version of EPO, the drug commonly used by cyclists in the 1990s and 2000s.

This is not the first time that the 32-year-old has found himself embroiled in a doping scandal. French police detained Di Gregorio while riding for Cofidis at the 2012 Tour de France after the Stage 9 time trial in connection to a doping investigation.

All charges were later dropped.

Read more about: